AR067995A1 - Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminales - Google Patents
Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminalesInfo
- Publication number
- AR067995A1 AR067995A1 ARP080103641A ARP080103641A AR067995A1 AR 067995 A1 AR067995 A1 AR 067995A1 AR P080103641 A ARP080103641 A AR P080103641A AR P080103641 A ARP080103641 A AR P080103641A AR 067995 A1 AR067995 A1 AR 067995A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmacos
- agents
- terminal extensions
- coupling
- specific site
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6805—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a vinca alkaloid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Abstract
La presente da a conocer anticuerpos (por ejemplo, anticuerpos IgG) que tienen extensiones C-terminales con contenido de cisteína que facilitan la conjugacion del anticuerpo a una molécula asociada (por ejemplo, un fármaco, una toxina, una molécula marcadora, proteína, radioisotopo u otro agente terapéutico). Se presentan métodos para la preparacion, deteccion y seleccion de anticuerpos de acuerdo con la presente solicitud.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95727107P | 2007-08-22 | 2007-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067995A1 true AR067995A1 (es) | 2009-10-28 |
Family
ID=40378584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103641A AR067995A1 (es) | 2007-08-22 | 2008-08-21 | Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminales |
Country Status (5)
Country | Link |
---|---|
US (1) | US8865875B2 (es) |
EP (1) | EP2185188B1 (es) |
AR (1) | AR067995A1 (es) |
TW (1) | TW200914045A (es) |
WO (1) | WO2009026274A1 (es) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
BRPI0921687A8 (pt) | 2008-11-03 | 2022-11-08 | Syntarga Bv | Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero. |
US8759322B2 (en) | 2008-11-05 | 2014-06-24 | National University Corporation Tokyo Medical And Dental University | Hyaluronic acid derivative and pharmaceutical composition thereof |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
WO2010096838A2 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proproteins and methods of use thereof |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
US8394922B2 (en) | 2009-08-03 | 2013-03-12 | Medarex, Inc. | Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
AR078471A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
ES2815678T3 (es) | 2010-04-21 | 2021-03-30 | Syntarga Bv | Conjugados de análogos de CC-1065 y conectores bifuncionales |
FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
US8956859B1 (en) | 2010-08-13 | 2015-02-17 | Aviex Technologies Llc | Compositions and methods for determining successful immunization by one or more vaccines |
CA2833477A1 (en) | 2011-04-21 | 2012-10-26 | Seattle Genetics, Inc. | Novel binder-drug conjugates (adcs) and their use |
RS59253B1 (sr) * | 2011-05-08 | 2019-10-31 | Legochem Biosciences Inc | Konjugati aktivnog agensa proteina i postupak za njihovo dobijanje |
US20140193436A1 (en) * | 2011-06-24 | 2014-07-10 | Centrose, Llc | Extracellular targeted drug conjugates |
DK2814829T3 (en) | 2012-02-13 | 2017-03-20 | Bristol Myers Squibb Co | RELATIONSHIPS, CONJUGATES THEREOF AND USES AND RELATED PROCEDURES |
MX353608B (es) * | 2012-02-24 | 2018-01-19 | Alteogen Inc | Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo. |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
RU2674003C2 (ru) | 2012-09-05 | 2018-12-04 | Чугаи Сейяку Кабусики Кайся | Производное гиалуроновой кислоты, содержащее аминокислотную и стерильную группы, введенные в него |
KR101419884B1 (ko) | 2012-11-27 | 2014-07-16 | (주)알테오젠 | 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물 |
EA201591131A1 (ru) | 2012-12-13 | 2015-12-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Днк-конструкции антитела и способ их применения |
LT2956173T (lt) | 2013-02-14 | 2017-06-26 | Bristol-Myers Squibb Company | Tubulizino junginiai, gavimo ir panaudojimo būdai |
US10260038B2 (en) | 2013-05-10 | 2019-04-16 | Whitehead Institute For Biomedical Research | Protein modification of living cells using sortase |
US10471099B2 (en) | 2013-05-10 | 2019-11-12 | Whitehead Institute For Biomedical Research | In vitro production of red blood cells with proteins comprising sortase recognition motifs |
BR112015032200A2 (pt) * | 2013-06-24 | 2017-11-21 | Hanwha Chemical Corp | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo |
AU2014332442B2 (en) | 2013-08-26 | 2019-12-19 | Biontech Research And Development, Inc. | Nucleic acids encoding human antibodies to Sialyl-Lewis |
ES2871418T3 (es) | 2013-08-28 | 2021-10-28 | Abbvie Stemcentrx Llc | Composiciones y métodos de conjugación de anticuerpos específicos de sitio |
PE20160678A1 (es) | 2013-10-18 | 2016-08-06 | Deutsches Krebsforsch | Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata |
KR20160070191A (ko) | 2013-11-06 | 2016-06-17 | 스템센트알엑스 인코포레이티드 | 신규한 항-클라우딘 항체 및 사용 방법 |
US10556024B2 (en) | 2013-11-13 | 2020-02-11 | Whitehead Institute For Biomedical Research | 18F labeling of proteins using sortases |
EP2873680A1 (en) | 2013-11-13 | 2015-05-20 | F.Hoffmann-La Roche Ag | Oligopeptide and methods for producing conjugates thereof |
AU2014361856A1 (en) | 2013-12-12 | 2016-06-30 | Abbvie Stemcentrx Llc | Novel anti-DPEP3 antibodies and methods of use |
CA2934818C (en) * | 2013-12-23 | 2022-05-17 | John Babcook | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
BR112016014830A2 (pt) | 2013-12-23 | 2017-09-19 | Bayer Pharma AG | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp |
CN105899235B (zh) | 2014-01-10 | 2019-08-30 | 斯索恩生物制药有限公司 | 用于纯化cys连接的抗体-药物缀合物的方法 |
EP2899208A1 (en) * | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
CA2950602C (en) | 2014-06-04 | 2021-07-20 | MabVax Therapeutics, Inc. | Human monoclonal antibodies to ganglioside gd2 |
TW201617368A (zh) | 2014-09-05 | 2016-05-16 | 史坦森特瑞斯公司 | 新穎抗mfi2抗體及使用方法 |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
US10077287B2 (en) | 2014-11-10 | 2018-09-18 | Bristol-Myers Squibb Company | Tubulysin analogs and methods of making and use |
BR112017011556A2 (pt) | 2014-12-01 | 2018-03-06 | Inovio Pharmaceuticals Inc | métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição. |
ES2747386T3 (es) | 2015-01-14 | 2020-03-10 | Bristol Myers Squibb Co | Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso |
ES2736106T3 (es) | 2015-03-10 | 2019-12-26 | Bristol Myers Squibb Co | Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos |
AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
JP7251981B2 (ja) | 2016-03-24 | 2023-04-04 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
US11235065B2 (en) | 2016-04-06 | 2022-02-01 | Alteogen, Inc. | Antibody-drug conjugate comprising modified antibody |
WO2017176007A1 (ko) * | 2016-04-06 | 2017-10-12 | (주)알테오젠 | 변형항체를 포함하는 항체-약물 접합체 |
EP3471776B1 (en) | 2016-06-15 | 2022-05-04 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies |
KR102493853B1 (ko) | 2016-08-19 | 2023-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법 |
WO2018075842A1 (en) | 2016-10-20 | 2018-04-26 | Bristol-Myers Squibb Company | Condensed benzodiazepine derivatives and conjugates made therefrom |
NZ753324A (en) | 2016-12-09 | 2022-02-25 | Seagen Inc | Bivalent antibodies masked by coiled coils |
JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
JP7030811B2 (ja) | 2016-12-21 | 2022-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | Ksp阻害剤を有する特異的抗体-薬物コンジュゲート(adc) |
US20190351066A1 (en) | 2016-12-21 | 2019-11-21 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
TW201836647A (zh) * | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗-prlr抗體藥物軛合物(adc)及其用途 |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
CN111630069A (zh) | 2017-10-13 | 2020-09-04 | 勃林格殷格翰国际有限公司 | 针对Thomsen-nouvelle(Tn)抗原的人抗体 |
EP3712181B1 (en) | 2017-11-15 | 2022-10-26 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid derivative modified with polyethylene glycol |
US11485741B2 (en) | 2018-04-24 | 2022-11-01 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (TLR7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
PL3886914T3 (pl) | 2018-11-30 | 2023-05-08 | Bristol-Myers Squibb Company | Przeciwciało zawierające c-końcowe rozszerzenie łańcucha lekkiego zawierające glutaminę, jego koniugaty oraz metody i zastosowania |
CN113439084A (zh) * | 2019-01-30 | 2021-09-24 | 奥克兰联合服务有限公司 | 倍癌霉素类似物 |
TW202110878A (zh) * | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
WO2022026915A2 (en) * | 2020-07-31 | 2022-02-03 | Angiex, Inc. | Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4391904A (en) | 1979-12-26 | 1983-07-05 | Syva Company | Test strip kits in immunoassays and compositions therein |
CA1203164A (en) | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
US4912227A (en) | 1984-02-21 | 1990-03-27 | The Upjohn Company | 1,2,8,8A-tetrahydrocyclopropa(c)pyrrolo(3,2-e)-indol-4-(5H)-ones and related compounds |
US4978757A (en) | 1984-02-21 | 1990-12-18 | The Upjohn Company | 1,2,8,8a-tetrahydrocyclopropa (C) pyrrolo [3,2-e)]-indol-4(5H)-ones and related compounds |
US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
US5332837A (en) | 1986-12-19 | 1994-07-26 | The Upjohn Company | CC-1065 analogs |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質dc113 |
US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Dc―88a誘導体 |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
EP0527189A1 (en) | 1990-04-25 | 1993-02-17 | PHARMACIA & UPJOHN COMPANY | Novel cc-1065 analogs |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
JPH0597853A (ja) | 1991-10-07 | 1993-04-20 | Kyowa Hakko Kogyo Co Ltd | Dc−89誘導体の臭化水素酸塩 |
JPH07503132A (ja) | 1991-12-17 | 1995-04-06 | ジェンファーム インターナショナル,インコーポレイティド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
CA2165819C (en) | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | デュオカルマイシン誘導体の安定化法 |
EP0786252A4 (en) | 1994-09-30 | 1998-01-07 | Kyowa Hakko Kogyo Kk | ANTI-TUMOR AGENT |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
KR100942863B1 (ko) | 1999-08-24 | 2010-02-17 | 메다렉스, 인코포레이티드 | 인간 씨티엘에이-4 항체 및 그의 용도 |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US7087800B2 (en) | 2000-06-27 | 2006-08-08 | Mitsubishi Gas Chemical Company, Inc | Process for producing a polyol |
EP1324778A2 (en) | 2000-10-02 | 2003-07-09 | Arizeke Pharmaceuticals, Inc. | Compositions and methods for the transport of biologically active agents across cellular barriers |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
KR100583331B1 (ko) | 2001-05-11 | 2006-05-26 | 기린 비루 가부시키가이샤 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물 |
CN101671335A (zh) | 2001-05-31 | 2010-03-17 | 梅达莱克斯公司 | 细胞毒素、其有用的前体药物、连接基团和稳定剂 |
US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
KR100668538B1 (ko) | 2002-01-09 | 2007-01-16 | 메다렉스, 인코포레이티드 | Cd30에 대한 인간 모노클로날 항체 |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
CA2504818C (en) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
ES2347959T3 (es) * | 2003-02-20 | 2010-11-26 | Seattle Genetics, Inc. | Conjugados de anticuerpos anti-cd70-farmaco y su uso para el tratamiento del cancer. |
JP4753867B2 (ja) | 2003-04-15 | 2011-08-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | ヒトil−18を含むコンジュゲートおよびその置換変異体 |
WO2005010048A2 (en) | 2003-07-22 | 2005-02-03 | Schering Aktiengesellschaft | Rg1 antibodies and uses thereof |
US20050266008A1 (en) | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
KR20140084242A (ko) * | 2005-06-20 | 2014-07-04 | 피에스엠에이 디벨롭먼트 캄파니, 엘엘씨 | Psma 항체-약물 접합체 |
US8097703B2 (en) | 2005-06-20 | 2012-01-17 | Medarex, Inc. | CD19 antibodies and their uses |
CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
AU2006294554B2 (en) | 2005-09-26 | 2013-03-21 | E. R. Squibb & Sons, L.L.C. | Antibody-drug conjugates and methods of use |
ES2375843T3 (es) | 2005-10-26 | 2012-03-06 | Medarex, Inc. | Procedimientos y compuestos para la preparación de an�?logos de cc-1065. |
WO2007059404A2 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
AU2006321553B2 (en) | 2005-12-08 | 2012-03-08 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to O8E |
PL1957539T3 (pl) | 2005-12-08 | 2013-08-30 | Squibb & Sons Llc | Ludzkie przeciwciała monoklonalne przeciwko białku kinazy tyrozynowej 7 (PTK7) i ich zastosowanie |
KR100673965B1 (ko) | 2006-01-11 | 2007-01-24 | 삼성테크윈 주식회사 | 인쇄회로기판 및 반도체 패키지 제조방법 |
KR100650043B1 (ko) | 2006-01-31 | 2006-11-28 | (주)아모레퍼시픽 | 피부탄력 개선용 유화 조성물 |
NZ578354A (en) | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
TWI412367B (zh) * | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
AR065404A1 (es) | 2007-02-21 | 2009-06-03 | Medarex Inc | Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero |
EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
EP2195017B1 (en) | 2007-10-01 | 2014-10-22 | Bristol-Myers Squibb Company | Human antibodies that bind mesothelin, and uses thereof |
RU2505544C2 (ru) | 2007-10-19 | 2014-01-27 | Дженентек, Инк. | Антитела против tenb2, сконструированные с цистеином, и конъюгаты антитело - лекарственное средство |
-
2008
- 2008-08-19 WO PCT/US2008/073569 patent/WO2009026274A1/en active Application Filing
- 2008-08-19 US US12/674,503 patent/US8865875B2/en active Active
- 2008-08-19 EP EP08798164.3A patent/EP2185188B1/en not_active Not-in-force
- 2008-08-21 AR ARP080103641A patent/AR067995A1/es unknown
- 2008-08-22 TW TW097132290A patent/TW200914045A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US8865875B2 (en) | 2014-10-21 |
TW200914045A (en) | 2009-04-01 |
EP2185188A4 (en) | 2011-07-13 |
EP2185188B1 (en) | 2014-08-06 |
EP2185188A1 (en) | 2010-05-19 |
US20110280891A1 (en) | 2011-11-17 |
WO2009026274A1 (en) | 2009-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067995A1 (es) | Acoplamiento en sitio especifico de farmacos u otros agentes a anticuerpos disenados con extensiones c-terminales | |
CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
JOP20190155A1 (ar) | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
UY32609A (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteína | |
ATE521366T1 (de) | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen | |
AR069747A1 (es) | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion | |
CL2008003074A1 (es) | Anticuerpo anti-tenb2 que comprende uno o mas aminoacidos libres de cisteinas de una secuencia definida; metodo para determinar la presencia de una proteina tenb2 en una muestra sospechosa que contiene la proteina; formulacion farmaceutica que comprende el anticuerpo; compuesto de un conjugado y un farmaco. | |
ECSP13012792A (es) | Composiciones farmacéuticas que comprenden anticuerpos humanos frente a pcsk9 | |
CR20120506A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
BR122018012430B8 (pt) | anticorpo monoclonal que se liga a pcsk9 humana, e, composição farmacêutica | |
BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
NZ711567A (en) | Antibody formulations | |
CY1118153T1 (el) | Αγωγη μικροβιακων μολυνσεων | |
BRPI0611414B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos | |
BR112012013975A2 (pt) | anticorpos monoclonais que se ligam b7h6 e usos dos mesmo | |
CL2008002923A1 (es) | Anticuerpo monoclonal humano aislado porque se adhiere a mesotelina humana; composicion que comprende dicho anticuerpo; conjugado entre anticuerpo y agente terapeutico; molecula de acido nucleico que codifica el anticuerpo; uso para preparar un medicamento para tratar cancer. | |
ECSP077261A (es) | Composición de anticuerpo her2 | |
MY169147A (en) | Drug-protein conjugates | |
AR077998A1 (es) | Proteinas terapeuticas de union a dll4 | |
NI201000042A (es) | Anticuerpos anti-il-12/23p40, epitopes, formulaciones, composiciones, métodos y usos. | |
BRPI0518762A2 (pt) | fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga | |
BR112013015786A2 (pt) | composição de agente de formação de imagem, método de formação de imagem de pelo menos uma parte de um indivíduo, e, método para preparar uma composição de polipeptídeo conjugado com quelante | |
EA200970469A1 (ru) | Антитела-агонисты рецептора trkb и их применение | |
MA32288B1 (fr) | Nouveaux anticorps utiles pour le traitement du cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |